Development stage company treating periprosthetic joint infection with localized drug delivery. Its lead program FC001 and second program FC002 both hold FDA Qualified Infectious Disease Product designation.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
No Spam. Unsubscribe anytime.